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Background: Systematic reviews represent one of the most important tools for knowledge translation but users
often struggle with understanding and interpreting their results. GRADE Summary-of-Findings tables have been
developed to display results of systematic reviews in a concise and transparent manner. The current format of the
Summary-of-Findings tables for presenting risks and quality of evidence improves understanding and assists users
with finding key information from the systematic review. However, it has been suggested that additional methods
to present risks and display results in the Summary-of-Findings tables are needed.
Methods/Design: We will conduct a non-inferiority parallel-armed randomized controlled trial to determine
whether an alternative format to present risks and display Summary-of-Findings tables is not inferior compared to
the current standard format. We will measure participant understanding, accessibility of the information, satisfaction,
and preference for both formats. We will invite systematic review users to participate (that is clinicians, guideline
developers, and researchers). The data collection process will be undertaken using the online 'Survey Monkey'
system. For the primary outcome understanding, non-inferiority of the alternative format (Table A) to the current
standard format (Table C) of Summary-of-Findings tables will be claimed if the upper limit of a 1-sided 95%
confidence interval (for the difference of proportion of participants answering correctly a given question) excluded
a difference in favor of the current format of more than 10%.
Discussion: This study represents an effort to provide systematic reviewers with additional options to display
review results using Summary-of-Findings tables. In this way, review authors will have a variety of methods to
present risks and more flexibility to choose the most appropriate table features to display (that is optional columns,
risks expressions, complementary methods to display continuous outcomes, and so on).
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Systematic reviews play a major role in informing
decision-making for clinicians, policy-makers, guideline
developers, and other stakeholders [1,2]; however, their
results are not always easy to understand and interpret.
Studies regarding the use and interpretation of evidence
to inform health care decisions have shown that text-
reported information about a treatment effect is incon-
sistently interpreted [3,4], and numerical results of risks
may be difficult to understand, even for educated users
[5].We previously [6] conducted a systematic review to study
the effects of using alternative statistical presentations
for reporting risk and risk reduction on understanding,
perception, persuasiveness and behavior of health pro-
fessionals, policy-makers, and consumers. Participants
better understood risks expressed as natural frequencies
(that is 15 out of 100) compared to risks expressed as
probabilities (that is 15%). Relative risk reductions (RRR)
were equally understood compared to absolute risk re-
ductions (ARR), but better understood than number
needed to treat (NNT), in particular when baseline risks
were not shown. However, RRR were perceived as (mis-
leadingly) larger and more persuasive than both ARR
and NNT. These findings highlight the importance of
appropriate presentation of systematic review results on
users’ understanding, and perception.
The 'Grading of Recommendations Assessment, De-
velopment and Evaluation' (GRADE) system [7-12] is a
widely accepted approach for developing and presenting
summaries of evidence for both systematic reviews and
clinical guidelines in a standardized and transparent
manner [13]. The aim of this approach is to summarize
the most important results from a systematic review in
absolute and relative terms, be explicit about patient-
important benefits and harms, and report the quality of
the evidence (also called 'confidence in the effect esti-
mates') for each outcome and across outcomes, in such a
way that clinicians, policy- makers, and consumers can
use reviews’ results efficiently and reliably. To accomplish
this goal, the GRADE approach proposes the use of 'Sum-
mary-of-Findings' (SoF) tables and evidence profiles [14].
SoF tables have undergone deliberate development.
The current format and content of SoF tables are based
on user-testing studies, stakeholder feedback, and two
randomized controlled trials [15-17]. These studies
showed that SoF tables (incorporated in systematic re-
views) significantly improved understanding (93% versus
44% (P = 0.003)) and the ability to find critical informa-
tion (68% versus 40% (P = 0.021)) compared to those
without SoF tables that report results only in a narrative
way [17]. In another randomized trial, it was found that
formatting modification of GRADE evidence profiles can
increase the comprehension of key findings ranging be-
tween 5 to 47% [18].Since 2004, The Cochrane Collaboration has been in-
tensively working on the implementation of SoF tables
in their reviews. By 2014, more than 600 SoF tables had
been published across review groups (Langendam et al:
Improving GRADE evidence tables: A systematic survey
of explanatory footnotes and judgments in Summary of
Findings Tables and Evidence Profiles shows more guid-
ance is needed, manuscript in preparation). However, it
has been noticed that the current standard format may
need to be adapted depending on specific review charac-
teristics. For example, the current SoF table format does
not provide specific guidance for scenarios such as the
narrative reporting of results when a meta-analysis was
not undertaken nor alternative formats of presenting
continuous and dichotomous outcomes. The inclusion
of alternative presentations of risks in SoF tables in-
cluded in systematic reviews would allow authors to
choose from a variety of scientifically tested items that
can be used to fit into the users’ needs.
Considering the above, the aim of this trial will be to
determine whether new alternative SoF table format is
not inferior compared to current standard format. Infer-
iority will be assessed by: understanding; perceived ac-
cessibility; satisfaction; and preference by health care
professionals, guideline developers, and researchers that
use and/or develop systematic reviews.
Methods
The following description of methods and analysis of
this trial follows the latest guidance by the Consolidated
Standards of Reporting Trials (CONSORT) group in its
extension for reporting of non-inferiority and equiva-
lence randomized trials [19] and the SPIRIT (Standard
Protocol Items: Recommendations for Interventional Tri-
als) statement [20]. The protocol of this study was regis-
tered in the clinicaltrials.gov database (NCT02022631).
Overview of the design
We will conduct a parallel-armed, non-inferiority ran-
domized trial comparing a new alternative format of SoF
tables with current format. We will contact systematic
review users by Email and ask them to fill a question-
naire developed using the 'Survey Monkey' online sys-
tem. The data collection form will include questions
about baseline information (demographic characteristics,
background, familiarity with systematic reviews and the
GRADE system, and so on). Then, participants will be
randomly assigned to one of two SoF tables, either the
one in the alternative format or the one with the current
format (See Figure 1). Randomization will be stratified
according to participants’ background (health profes-
sional, guideline developer, researcher). They will be
asked to answer questions to determine understanding,
accessibility of information, and satisfaction with the
Email invitation to participate
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Figure 1 Study design and flow-chart.
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will show them the other table format to which they
were not initially allocated in order to test their prefer-
ence for either one.
Participants
Selection criteria
Participants will be eligible if they consider themselves
as systematic review users. For the purpose of this trial,
a user is defined as someone who has used Cochrane
and/or non-Cochrane systematic reviews at least twice a
year to answer clinical questions on a patient-health pro-
fessional basis, inform the process of making recommen-
dations for clinical practice guidelines, inform other
types of evidence-based decision-making, or to use them
for research purposes. We will include three target pop-
ulations: (1) health professionals working in primary,
secondary, or tertiary care, (2) clinical practice guidelines
developers, and (3) researchers. We will classify as clini-
cians those who report at least 50% of total time dedi-
cated to clinical practice. To be considered a guideline
developer, participants should declare having partici-
pated in at least 1 clinical practice guideline during the
last 2 years. Finally, participants who declare dedicating
more than 70% of their time to conduct research (forexample, methodologists, epidemiologists, statisticians,
and so on) will be classified as researchers. Compared to
previous trials testing SoF tables, this study includes
similar populations [17,18].Setting and recruitment
We will recruit participants from Europe, North America,
South America, Africa and Australasia. We will contact
people through various networks: Cochrane review groups
and the networks of the co-authors who interact with
guideline developers, researchers and systematic reviewers.
Potentially eligible participants will receive a structured
and standardized invitation with a link to access the 'Sur-
vey Monkey' questionnaire. Using this online system, we
will determine whether the participants are eligible based
on the selection criteria. All eligible participants will be
provided with a brief explanation of the study and an on-
line informed consent. We will also recruit participants at
workshops, conferences and other research events. The
Hamilton Health Sciences/Faculty of Health Sciences Re-
search Ethics Board at McMaster University reviewed the
protocol and approved it to be conducted without need of
official approval, arguing that this trial is a quality im-
provement study with almost no risk to participants.
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waived by the Ethics Board.
Intervention and comparison
In this trial, one table displaying an alternative format of
SoF will be tested against the current table format. In
both SoF tables, the clinical question of the review in
terms of patients, setting, intervention, comparator, out-
comes, and the complementary information included as
footnotes, will be the same. The only differences be-
tween the current and alternative SoF table formats will
be the methods to either display the same data in a dif-
ferent way or to provide complementary data to the one
shown in the current format (for example, risk differ-
ence). The SoF table in the current format that will be
used in the control group is similar to the tables tested
in previous trials on the same topic. With slight modifi-
cations, the SoF tables that will be used in this study are
based on a real Cochrane systematic review conducted
by Johnston et al. [21], titled Probiotics for the preven-
tion of pediatric antibiotic-associated diarrhea. A com-
parison between the items included in the alternative
and current SoF table formats is listed in Table 1. Figures 2
and 3 correspond to the alternative (Table A) and current
formats (Table C) of SoF table formats respectively.
Randomization
Once the potentially eligible participants have completed
the general information and background questionnaire,
those who meet the selection criteria will be stratified
according to self-reporting data as clinicians, guideline
developers, or researchers and randomly allocated to
one of the 2 SoF tables in a 1:1 ratio. To minimize miss-
ing data, the 'Survey Monkey' system will randomly as-
sign participants to one of the SoF tables immediately
after stratification, providing them with a link to access
the questionnaires and tables.Table 1 Comparison between items included in the current a
Current formats (Table C)
1 Inclusion of the number of participants and studies column
2 Quality of evidence presented with symbols and labeled as High,
Moderate, Low, or Very low. Reasons for downgrading presented
in the footnotes
3 'Footnotes' label
4 Baseline risk and corresponding risk expressed as natural frequenc
5 No column presenting absolute risk reduction (risk difference) or
mean difference
6 Comments column included
7 No 'What happens' columna
8 Description of the GRADE Working Group grades of evidence
definitions below the table
aThe 'What happens' column aims to summarize both the treatment effect and theConcealment of allocation
Since random allocation of participants to a SoF table is
done automatically by the 'Survey Monkey' system in
real time following an unknown algorithm, without a pre-
specified sequence, it will be not known in advance to
which group the next participant will be allocated. There-
fore, in the trial allocation concealment is guaranteed.
Blinding
The data collection process will be conducted automat-
ically by the 'Survey Monkey' web platform. The SoF
table formats will be labeled as A, or C; thus, partici-
pants will be allocated to Table A or C without any other
information about the nature of the tables. Participants
will be blinded to whether the table they are exposed to
was the one in the current or alternative format while
the outcomes understanding, accessibility, and satisfac-
tion, are assessed. The only exception will be the out-
come preference, as the only way to measure it is
comparing the table to which they are randomized with
the table to which they were not allocated. Therefore,
participant blinding will be broken only after they have
fully assessed the SoF table to which they were initially
randomized. Once the data collection process is com-
pleted, the database will be prepared for statistical ana-
lysis and interpretation in a blinded fashion. Finally, the
labels will be revealed after the analysis is done.
Outcomes
The outcome assessments will be defined and conducted
as follow:
Primary outcome
Understanding It is defined as the correct comprehen-
sion of key findings. We will frame seven multiple-
choice questions about key concepts in the table with
five response alternatives for each question and only onend alternative Summary-of-Findings (SoF) table formats
Alternative formats (Table A)
Exclusion of the number of participants and studies column.
Information presented in the outcomes column
Quality of evidence presented along with main reasons for
downgrading in the same column (for example, Moderate
due to imprecision)
'Explanations' label
ies Baseline risk and corresponding risk expressed as percentages
Inclusion of a column presenting absolute risk reduction
(risk difference) or mean difference
Comments column deleted
'What happens' column includeda
No description of the GRADE Working Group grades of
evidence definitions
quality of the evidence in one short narrative statement.
Figure 2 Alternative Summary-of-Findings (SoF) table format (Table A).
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Figure 3 Current Summary-of-Findings (SoF) table format (Table C).
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rect answers between groups per question. A 10% differ-
ence was defined as the minimal important difference
between groups.
Secondary outcomes
Accessibility of information This outcome considers 3
domains: (1) how easy it is to find critical information in
the table; (2) how easy it is to understand the informa-
tion, and (3) whether the information is presented in a
way that is helpful for decision-making. These three do-
mains will be measured by presenting participants with
3 statements for which they have to indicate the degree
of agreement: 'It was easy to find the information about
the effects'; 'It was easy to understand the information',
and 'The information is presented in a way that would
help me making a decision'. Agreement will be measured
using a 7-point Likert-type scale (1 = I strongly disagree,
2 = I disagree, 3 = I somewhat disagree, 4 = Neither agree
nor disagree, 5 = I somewhat agree, 6 = I agree, and 7 = I
strongly agree). The outcome overall accessibility of in-
formation will be measured directly using a 5-point
Likert scale (1 = Very inaccessible, 2 = Inaccessible, 3 =
Neither inaccessible nor accessible, 4 = Accessible, 5 =
Very accessible), asking the participant to consider the 3
above domains together. For all these measures, we will
compare the means per group in each domain and overall.
Satisfaction Measured at an item level, we will ask par-
ticipants which formatting features satisfy them the most
(for example, 'In Table A, we included a column called
'What happens'. The purpose of this column is to assist
users on the interpretation of both review results and
quality of the evidence. Do you think this column should
be included as an available feature in future versions of
SoF tables?'). It will be measured as a dichotomous out-
come and we will compare proportions per group.
Preference Participants will answer the question: Be-
tween alternative (Table A) and current format (Table C)
of SoF table, 'which table do you prefer?' It will be mea-





Accessibility of information (at a domain level) Ordinal (treated as continuo
Overall accessibility of information Ordinal (treated as continuo
Satisfaction Dichotomous
Preference ContinuousTable A, 2 = I prefer Table A, 3 = I somewhat prefer
Table A, 4 = Same preference for Table A or C, 5 = I
somewhat prefer Table C, 6 = I prefer Table C, 7 = I
strongly prefer Table C), and it will be treated as a con-
tinuous outcome.
The outcomes considered in this trials are similar to
the ones measured in previous randomized controlled
trials and other observational studies testing SoF ta-
bles [16-18]. Table 2 presents a summary of outcomes
measures.
Sample size calculation
Sample size estimation was conducted using the soft-
ware Stata/SE 10.1 (StataCorp., College Station, TX,
USA) for Macintosh (Apple Inc., Cupertino, CA, USA).
Based on the primary outcome, the null hypothesis was
that the proportion of participants who answer the un-
derstanding questions correctly is lower in the alterna-
tive format table group compared to the current format
table group, while the alternative hypothesis was that the
proportion of participants correctly answering the ques-
tions in the alternative format table group is at least the
same or higher compared to the current format table
group (See Equation 1):
Null hypothesis
H0 : CF SoF tables – ANF SoF tables 3 NIM CF is superior to ANFð Þ
ð1Þ
Alternative hypothesis
Ha:CF SoF tables – ANF SoF tables ≤ NIM ANF is not inferior to CFð Þ
ð2Þ
NIM: non-inferiority margin; CF: current format; ANF:
alternative or narrative format
The proportion of participants correctly answering
questions about understanding in similar randomized
controlled trials that tested the current SoF table format
was between 80 to 87% [17,18], and we expect, at least,
the same percentage in the group of participants ran-
domized to the alternative format of SoF table. A non-Measure Analysis method
% of participants with correct answers Multiple logistic regression
us) 1-7 Likert scale Multiple linear regression
us) 1-5 Likert-type scale Multiple linear regression
% of participants satisfied with an item Chi-square test
1-7 Likert scale Multiple linear regression
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1:1 participants will be used. If there is truly no differ-
ence between the current and the alternative table for-
mat, then 280 participants are required to be 80% sure
that the upper limit of a 1-sided 95% confidence interval
(CI) will exclude a difference in favor of the current SoF
table format of more than 10%. Assuming that 10% of
participants would not complete the questionnaire, we
aim to recruit a total of 308 participants. Linear and lo-
gistic regressions will be used as a method of analysis.
According to Hsieh et al. [22], when more than one co-
variate is included in the model, a variance inflation fac-
tor should be added to the typical univariate analysis to
obtain the required sample size. Equation 3 represents
the variance inflation factor cited, where b1 represents
the maximum likelihood estimate of β1, varp(b1) corre-
sponds to the variance of b1 that it is approximated from
a one parameter model to a multivariate case when
multiplied by 1/(1 - ρ21.23….p), where ρ1.23….p is the mul-
tiple correlation coefficient associating X1 with X2,…Xp.
From unvariate to multivariate regression model sam-
ple size estimation:
varp b1ð Þ ¼ var1 b1ð Þ= 1‐ρ21:23…:p
 
ð3Þ
Since this is a clinical trial in which participants will
be allocated to the study arms randomly, it can be as-
sumed that no correlation exists between being assigned
to a particular arm and any of the predictors considered
for analysis. Then, the value of ρ in the current study is
zero, and the estimated sample size is the one described
above.
Statistical analysis
Descriptive and exploratory analysis
In both trials, descriptive analysis will include partici-
pants’ baseline characteristics and outcomes, means and
standard deviations (SD) for continuous variables and
proportions for categorical variables.
Inferential analysis
The primary outcome (understanding) will be estimated
as the proportion of participants correctly answering
each question per group. Data regarding this outcome
will be analyzed using a multiple logistic regression per
question, where the main predictor will be the arm to
which participants were allocated (dichotomous - 2 cat-
egories). Other potential predictors to include in the
model are participant strata (nominal - 3 categories),
years of experience (nominal - 5 categories), familiarity
with the GRADE approach (dichotomous - 2 categories),
and previous education in health research methodology
or epidemiology (ordinal - 3 categories). To adjust for
multiplicity, the P-value will be modified using theBonferroni correction for 7 multiple comparisons
(<0.0035, CIs will be constructed with corresponding 1-
sided z score 2.7).
For the secondary outcome, accessibility of information,
we will calculate means, SDs and 95% CIs per domain. Data
regarding this outcome will be analyzed using multiple lin-
ear regression where the main pre.dictor will be the arm to
which participants were allocated (dichotomous - 2 cat-
egories). Other potential predictors included in the model
will be participant strata (nominal - 3 categories), years of
experience (nominal - 5 categories), familiarity with the
GRADE approach (dichotomous - 2 categories), and previ-
ous education in health research methodology or epidemi-
ology (ordinal - 3 categories). To adjust for multiplicity, the
P-value will be modified using the Bonferroni correction
for 4 multiple comparisons (<0.0125).
The secondary outcome, satisfaction, will be measured
at an item level. The proportion of participants satisfied
with either item included in Table A or C will be calcu-
lated per group.
For the secondary outcome, preference, linear regres-
sions will be used. Since this outcome is obtained from a
direct comparison of the tables (blinding is disclosed),
there will be no main predictor of interest. However, we
will control for the order in which the tables were shown
to the participants (dichotomous - 2 categories). Other
potential predictors to include in the model will be partici-
pant strata (nominal - 3 categories), years of experience
(nominal - 5 categories), familiarity with the GRADE ap-
proach (dichotomous - 2 categories), and previous educa-
tion in health research methodology or epidemiology
(ordinal - 3 categories).Evaluation of the models
All the predictors presented along with the outcomes
were selected because they have been considered poten-
tially related to that particular outcome and could help
to predict the observed variability. Harrell’s method [23]
will be applied for variable reduction. First, the model
will be run including only one key predictor variable.
Then, in an iterative process each predictor will be in-
cluded along with the key predictor cited above in a
model. If in any of these steps a predictor changes the
parameter estimate by more than 10%, it will be
retained in the model. Finally, the definitive multivari-
able model will consist of the key predictor chosen and
all the variables that changed the parameter estimate by
more than 10%. The key predictor for the outcomes un-
derstanding, and accessibility of information will be the
arm to which the participants were randomly allocated.
For the outcome participants’ preference for a table, the
order in which the tables were shown will be the key
predictor.
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For the primary outcome understanding, non-inferiority
of the alternative (Table A) format to the current stand-
ard format (Table C) of SoF tables will be claimed if the
upper limit of the CI (for the difference of proportion of
participants answering correctly a given question, using
Table C as reference) is lower than a non-inferiority
margin of 10%. This approach is more informative as
each question is related to a particular item under test-
ing in the tables. Only the test for superiority will be ap-
plied to the secondary outcomes.
Dealing with dropouts and missing data
Since this trial will use an online system to allocate partici-
pants and collect baseline and outcome data, participants
can leave the studies at any time. To minimize the possibil-
ity of dropouts and missing data, several strategies will be
considered: (1) to reduce the level of burden to participants,
only one link will be sent, which includes all the required
questionnaires and material, (2) the random allocation to
the studies arms will occur after collecting all the baseline
characteristics, allowing the minimization of the likelihood
of missing answers, (3) the questions will be set in
mandatory response mode, so the participants cannot con-
tinue to the next form page until all the questions from the
current page are answered, (4) the questions measuring
outcomes will be designed as 'one-click questions', avoiding
open-ended questions as much as possible, and (5) from
the beginning of the data collection, randomization, and
outcome assessment, a short process will be designed as
participants would require no more than 15 to 20 minutes
to respond.
Since the 'Survey Monkey' system allows setting each
question as requiring an answer before moving to the next
section, missing data for a couple of questions within a
questionnaire is not possible. However, as in any type of re-
search, participants can leave the study whenever they
want. When this happens, all the answers before leaving
will be registered in our database, and all the ones that were
not answered will be classified as missing from that point
in the questionnaire until the end. If a participant leaves the
study before randomization, the participant will be ex-
cluded and thus we will not consider this as missing partici-
pant data. On the other hand, if the person is randomized
and does not complete the questions, an available case ana-
lysis will be used (that is using the data available until the
participant left the study). By the nature of the online sys-
tem used to allocate participants, there is no possibility for
participants to cross over to the other study arm.
Discussion
This study represents an effort to provide systematic re-
viewers with additional options to display review results
using SoF tables. Since the current format of SoF tablehas shown to improve understanding and facilitate the
rapid retrieval of key findings, with an average of 90 sec-
onds compared to the full text review [17], this time, we
plan to conduct a non-inferiority trial with the aim to
test an alternative format that can perform at least as ef-
fectively as the current one (comparison at a table level).
In this way, review authors will have a variety of
methods to present risks and more flexibility to choose
the most appropriate table features to display (these be-
ing optional columns, risks expressions, complementary
methods to display continuous outcomes, and so on).
The current trial has several strengths. First, it utilizes
feedback and comments from a broad audience of
GRADE users with different interests. This feedback in-
formed a series of iterative user-testing rounds to exam-
ine the potential usefulness of several alternative formats
for SoF tables. Second, it builds upon previous random-
ized controlled trials comparing the validated current
standard format with the new alternative format pro-
posed. Third, following methodological suggestions pro-
vided by Akl et al.[6] for further trials conducted in the
same field, we designed a methodologically sound non-
inferiority parallel-armed randomized controlled trial.
Fourth, it will include participants from different back-
grounds, settings (these being clinicians, guideline devel-
opers, and researchers), and different languages, which
increases the generalizability of the findings. Fifth, this
trial follows the recommendations for reporting provided
by the CONSORT group in its extension for reporting of
non-inferiority and equivalence randomized trials [19].
This study also has some limitations. First, since the
data collection is conducted using an online system,
there will be limited control over the environment in
which the questionnaire is completed (that is whether it
is completed by the same person that the link was sent
to, whether the participant used additional information
while answering the questions that measures the out-
comes, and so on). Second, multiplicity and the corre-
sponding adjustments may influence the precision of the
CIs, a situation that may facilitate to find inconclusive
results.
Trials status
In participants’ recruitment phase.
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